Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 8.74M P/E - EPS this Y - Ern Qtrly Grth -
Income -4.56M Forward P/E - EPS next Y - 50D Avg Chg -
Sales 148.98k PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -36.00%
Recommedations - Quick Ratio 0.08 Shares Outstanding 131.85M 52W Low Chg 22.00%
Insider Own 34.93% ROA -37.06% Shares Float 84.80M Beta 0.55
Inst Own - ROE - Shares Shorted/Prior -/- Price 0.07
Gross Margin 73.48% Profit Margin - Avg. Volume 3,705 Target Price -
Oper. Margin -2,248.93% Earnings Date May 23 Volume 100 Change 0.00%
About KANE BIOTECH INC

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

KANE BIOTECH INC News
04/16/24 Kane Biotech to Host Investor Webinar
04/15/24 Kane Biotech Announces Closing of the Sale of STEM Animal Health to Dechra Veterinary Products
04/11/24 Kane Biotech Announces Agreement in Principle for the Sale of its Interest in STEM Animal Health
03/28/24 Kane Biotech Full Year 2023 Earnings: CA$0.04 loss per share (vs CA$0.032 loss in FY 2022)
03/26/24 Kane Biotech Announces Fourth Quarter and Full Year 2023 Financial Results
03/20/24 Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health
03/19/24 Kane Biotech to Release Fourth Quarter and Full Year 2023 Financial Results on March 26, 2024 – Conference Call to Follow
03/08/24 Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award
02/22/24 Dr. Robert Huizinga Elected to the Kane Biotech Board and Appointed Executive Chair
01/31/24 Kane Biotech Files New Patent on revyve™ Antimicrobial Wound Gel Spray
12:03 PM Kane Biotech to Present its revyve™ Antimicrobial Wound Gel at Boswick Burn and Wound Care Symposium
01/18/24 Kane Biotech Announces Special Meeting of Shareholders
12/29/23 Kane Biotech Announces Correction to Press Release
12/28/23 Kane Biotech Announces Amendment to its Credit Facility
12/20/23 Kane Biotech Receives Offer for its Interest in STEM Animal Health
11/28/23 Kane Biotech Announces Improved Third Quarter 2023 Financial Results
11/21/23 Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
11/16/23 Kane Biotech Strengthens Board with Biotech Executive
11/02/23 Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
06:45 AM Kane Biotech to Exhibit at Symposium on Advanced Wound Care Fall Forum